This is an abstract and plain language summary of a regularly updated, systematic review prepared and maintained by The Cochrane Collaboration. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
The Cochrane Database of Systematic Reviews 2006 Issue 2
Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Stead LF, Lancaster T
There is no evidence that Nicobrevin aids long term smoking cessation
Nicobrevin is a proprietary product containing quinine, menthyl valerate, camphor and eucalyptus oil marketed as an aid to smoking cessation. No randomized trials with long term follow up of smoking status were identified, so there was no evidence to assess efficacy.
Nicobrevin is a proprietary product marketed as an aid to smoking cessation. It contains quinine, menthyl valerate, camphor and eucalyptus oil.
The objective of this review was to assess the effects of Nicobrevin on long term smoking cessation
We searched the Cochrane Tobacco Addiction Group trials register.
Randomized trials comparing Nicobrevin to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow up.
Data were sought on the outcome, method of randomization, and completeness of follow up.
We identified no trials meeting the full inclusion criteria including long-term follow up.
There is no evidence available from long-term trials that Nicobrevin can aid smoking cessation.
This is an abstract and plain language summary of a regularly updated, systematic review prepared and maintained by The Cochrane Collaboration. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
